What is the official website of Moderna ?

The official website of Moderna is https://www.modernatx.com/?tc=soc_7y8qkt&cc=1004.

What is Moderna's cybersecurity risk score?

Moderna has an AI-generated cybersecurity risk score of 748 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Moderna experienced?

According to Rankiteo, Moderna currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Moderna been affected by any supply chain cyber incidents ?

According to Rankiteo, Moderna has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Moderna have SOC 2 Type 1 certification ?

According to Rankiteo, Moderna is not certified under SOC 2 Type 1.

Does Moderna have SOC 2 Type 2 certification ?

According to Rankiteo, Moderna does not hold a SOC 2 Type 2 certification.

Does Moderna comply with GDPR ?

According to Rankiteo, Moderna is not listed as GDPR compliant.

Does Moderna have PCI DSS certification ?

According to Rankiteo, Moderna does not currently maintain PCI DSS compliance.

Does Moderna comply with HIPAA ?

According to Rankiteo, Moderna is not compliant with HIPAA regulations.

Does Moderna have ISO 27001 certification ?

According to Rankiteo,Moderna is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Moderna operate in ?

Moderna operates primarily in the Biotechnology Research industry.

How many employees does Moderna have ?

Moderna employs approximately 6,394 people worldwide.

Does Moderna own any subsidiaries ?

Moderna presently has no subsidiaries across any sectors.

How many LinkedIn followers does Moderna have ?

Moderna's official LinkedIn profile has approximately 747,362 followers.

What is the NAICS classification code for Moderna ?

Moderna is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Moderna have a Crunchbase profile ?

No, Moderna does not have a profile on Crunchbase.

Does Moderna have a LinkedIn profile ?

Yes, Moderna maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/modernatx.

How many cybersecurity incidents has Moderna experienced ?

As of June 16, 2026, Rankiteo reports that Moderna has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Moderna have ?

Moderna has an estimated 4,704 peer or competitor companies worldwide.

What types of cybersecurity incidents has Moderna faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Moderna

Boost Score +25 with badge (5 left)

748

/1000

Moderate

773

/1000

Fair

Moderna Vendor Cyber Rating & Cyber Score

modernatx.com

Add Your Compliance Badge

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health,

Moderna A.I CyberSecurity Scoring

Scoring History

Moderna

Moderna CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Moderna

Cyber Attack

5/2026

MOD1779345048

Moderna

Cyber Attack

12/2025

CANADYATLHUBEPI...

Loading…

A.I.

Moderna Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Moderna

Incidents vs Biotechnology Research Industry Avg (This Year)

Moderna has 0.0% fewer incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

Moderna has 6.54% fewer incidents than the average of all companies with at least one recorded incident.

Incident Types Moderna vs Biotechnology Research Industry Avg (This Year)

Moderna reported 1 incidents this year: 1 cyber attacks, 0 ransomware, 0 vulnerabilities, 0 data breaches, compared to industry peers with at least 1 incident.

Incident History - Moderna (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Moderna Subsidiaries

Parent Company

Moderna

Biotechnology Research

Website: https://www.modernatx.com/?tc=soc_7y8qkt&cc=1004

Company Size: 1,001-5,000 employees

No subsidiary data available for this company.

Loading…

Moderna Similar Companies

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Syneos Health

cb syneoshealth.com

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Loading…

NEWS

Moderna CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 04, 2026 09:50 PM

These Stocks Are Today’s Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More

Moderna shares jump after the vaccine maker says it has settled patent litigation tied to its Covid-19 shot.

Read Article

March 04, 2026 12:54 PM

CrowdStrike, Nvidia and Moderna rise premarket; Abercrombie & Fitch falls

Investing.com -- U.S. stock futures edged higher Wednesday, bouncing after earlier losses this week on reports that Iran may be suing for an...

Read Article

March 04, 2026 09:35 AM

Trending tickers: CrowdStrike, Moderna, Adidas, Vistry and Barratt Redrow

Cybersecurity firm CrowdStrike (CRWD) was in focus on Wednesday morning, after reporting its fourth quarter earnings, which came in slightly...

Read Article

March 04, 2026 01:49 AM

CRWD, MOBX, MU, TGT, MRNA: 5 Trending Stocks Today - CrowdStrike Holdings (NASDAQ:CRWD)

U.S. stocks finished Tuesday lower as mounting tensions in the conflict with Iran weighed on sentiment. The Dow Jones Industrial Average...

Read Article

February 18, 2026 08:00 AM

Moderna, FDA reach compromise to accelerate approval of mRNA flu vaccine

A first-of-its-kind mRNA vaccine for the flu developed by Moderna will be considered for approval by the U.S. Food and Drug Administration...

Read Article

February 18, 2026 08:00 AM

Article | FDA's reversal on Moderna flu shot bid followed White House pressure

The FDA's decision this week to reverse course and review Moderna's seasonal flu vaccine application followed a meeting in which President...

Read Article

February 18, 2026 08:00 AM

These Stocks Are Today’s Movers: Nvidia, Palantir, Garmin, Global Payments, Palo Alto, Moderna, Caesars, and More

Nvidia shares rise after Meta Platforms expands an existing partnership with the AI chip designer.

Read Article

February 12, 2026 08:00 AM

HHS’s side of the Moderna spat

With help from Lauren Gardner, Dana Nickel, Carmen Paun and Simon J. Levien. Driving the Day. A sign marks an entrance to a Moderna building...

Read Article

February 11, 2026 08:00 AM

Article | Federal health officials: Moderna bucked ‘very clear’ advice on flu vaccine trial design

Trump administration officials defended the Food and Drug Administration's decision last week to refuse reviewing Moderna's flu vaccine...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-53430

SUMMARY

Improper Handling of Highly Compressed Data (Data Amplification) vulnerability in elixir-grpc grpc (GRPC.Compressor.Gzip, GRPC.Message modules) allows a denial of service via a gzip decompression bomb. This vulnerability is associated with program files lib/grpc/compressor/gzip.ex, lib/grpc/message.ex and program routines 'Elixir.GRPC.Compressor.Gzip':decompress/1, 'Elixir.GRPC.Message':from_data/2. 'Elixir.GRPC.Compressor.Gzip':decompress/1 calls :zlib.gunzip/1 directly on attacker-controlled bytes with no decompressed-size limit, ratio check, or incremental decoding. Because this module is the registered gzip GRPC.Compressor implementation, it is invoked automatically whenever an incoming gRPC frame carries the grpc-encoding: gzip header. :zlib.gunzip/1 allocates the entire decompressed result as a single binary, so a small highly compressible payload (for example a few kilobytes of zeros, which gzip compresses at roughly 1000:1) expands to multiple gigabytes inside a single call. The max_receive_message_length limit is enforced only against the already-decompressed message, so it provides no protection. An unauthenticated remote peer can send a single crafted frame to exhaust the BEAM node's heap and trigger an out-of-memory kill. This issue affects grpc: from 0.4.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48854

SUMMARY

Allocation of Resources Without Limits or Throttling vulnerability in elixir-grpc grpc allows unauthenticated attackers to exhaust the BEAM's memory and crash the server by streaming a large or slow-trickle unary request body. 'Elixir.GRPC.Server.Adapters.Cowboy.Handler':read_full_body/3 (lib/grpc/server/adapters/cowboy/handler.ex) accumulates every received chunk into a single growing binary with no size cap. Additionally, when the client omits the grpc-timeout header, the per-chunk read timeout resolves to :infinity, allowing a slow-trickle client to keep the connection alive indefinitely while memory grows. A single connection is sufficient to exhaust server memory and crash the node. This issue affects grpc from 0.3.1 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48853

SUMMARY

Deserialization of Untrusted Data and Allocation of Resources Without Limits or Throttling vulnerabilities in elixir-grpc grpc allow unauthenticated attackers to crash the BEAM node via atom table exhaustion and, when a decoded term flows into a call site that invokes it, achieve remote code execution on the server. 'Elixir.GRPC.Codec.Erlpack':decode/2 (lib/grpc/codec/erlpack.ex) calls :erlang.binary_to_term/1 on the raw gRPC message body without the :safe option, no size bound, and no type guard. Any unauthenticated peer that sends a request with Content-Type: application/grpc+erlpack can send a crafted payload that mints arbitrary new atoms (which are never garbage-collected, exhausting the bounded atom table and crashing the VM) or that encodes a fun term which, if applied anywhere downstream, executes attacker-controlled code inside the server process. This issue affects grpc from 0.4.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48723

SUMMARY

The browserstack-cypress-cli is BrowserStack's CLI which allows users to run Cypress tests on BrowserStack. Versions prior to 1.36.4 are vulnerable to OS command injection via the cypress_config_file configuration parameter. In readCypressConfigUtil.js, the loadJsFile() function constructs a shell command by interpolating the user-controlled cypress_config_filepath value into a template literal, then executes it via child_process.execSync(). Shell metacharacters in the config path (specifically " and ;) allow breaking out of the quoted argument and injecting arbitrary commands. This issue has been fixed in version 1.36.6.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-48599

SUMMARY

Authorization Bypass Through User-Controlled Key vulnerability in elixir-grpc grpc allows authenticated attackers to access or modify resources belonging to other users by smuggling a conflicting value for any path-bound field via the query string or request body. In 'Elixir.GRPC.Server.Transcode':map_request/5 (lib/grpc/server/transcode.ex), all three clauses use Map.merge/2 with path bindings as the first argument, giving them the lowest merge precedence. A request such as GET /users/me/profile?user_id=victim (or a POST with {"user_id": "victim"} when body: "*") yields a decoded protobuf struct where the path-bound field carries the attacker-supplied value rather than the router-extracted value. Any handler that uses the path-bound field for authorization, multi-tenancy scoping, or ownership checks is silently bypassed. This issue affects grpc from 0.8.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 7.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…